S J Antonia Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

1/2022	Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
12/2021	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.
1/2020	Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
1/2018	Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

S J Antonia Research Topics

Disease

4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2018
3	Neoplasms (Cancer) 01/2016 - 04/2000
1	Disease Progression 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2018
1	Renal Cell Carcinoma (Grawitz Tumor) 04/2000

Drug/Important Bio-Agent (IBA)

2	durvalumabIBA 01/2022 - 01/2020
1	PlatinumIBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 12/2021
1	B7-H1 AntigenIBA 12/2021
1	Immune Checkpoint InhibitorsIBA 01/2018
1	EnzymesIBA 01/2018
1	Docetaxel (Taxotere)FDA Link 01/2018
1	NivolumabIBA 01/2018
1	Complementary DNA (cDNA)IBA 04/2000
1	NitrogenIBA 04/2000
1	Cancer VaccinesIBA 04/2000
1	Interleukin-2 (IL2)IBA 04/2000
1	VaccinesIBA 04/2000

Therapy/Procedure

2	Chemoradiotherapy 01/2022 - 01/2020
2	Immunotherapy 12/2021 - 05/2007
2	Therapeutics 01/2016 - 04/2000